| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tivantinib | CTRPv2 | pan-cancer | AAC | -0.0045 | 0.9 |
| mRNA | JW-480 | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.0072 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.0033 | 0.9 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |